analyst theodor oneil initi coverag co-diagnost inc
initi coverag co-diagnost inc buy rate price target
price target base discount valu futur earn
saturday feb fda issu emerg guidelin expand capac laboratori
test believ jumpstart demand codx coronaviru test
cdi develop new approach polymeras chain reaction test develop get
market quicker higher specif test multipl diseas type singl sampl fewer
believ global address market worth billion billion
believ dna test fastest-grow segment in-vitro diagnost test
anticip rise health care cost develop develop nation increasingli requir
health care system patient specif elimin wast misdiagnos ineffect critic
compon accur afford dna-bas diagnost cdi plan offer
multipl book
estim ep dollar revenu thousand
balanc million
debt million
note number may add due round full model back
risk includ extent outbreak regulatori approv abil commerci product
target deriv use discount futur earn model
compani descript co-diagnost inc develop robust innov molecular tool detect
infecti diseas liquid biopsi cancer screen agricultur applic
import disclosur found back report
initi coverag co-diagnost inc cdi buy rate price target
price target base discount valu futur earn
saturday feb fda issu emerg guidelin expand capac laboratori
test believ jumpstart demand codx coronaviru test
cdi develop new approach polymeras chain reaction test develop get
market quicker higher specif test multipl diseas type singl sampl fewer
believ global address market worth billion billion
believ dna test fastest-grow segment in-vitro diagnost test
anticip rise health care cost develop develop nation increasingli requir
health care system patient specif elimin wast misdiagnos ineffect critic
compon accur afford dna-bas diagnost cdi plan offer
sinc compani ipo report minim revenu recent quarter revenu
make signific progress get regulatori approv target market expect
year revenu growth still hurdl success compani commerci
product add scale certain test earn ce mark mean sell test
eu fda announc allow cdi test other use prior fda approv
share soar expect test revenu result major increas sale
turn depend larg part world popul becom ill time certainti
mani test need much revenu gener cdi fda prepar
emerg test isnt need share may return previou level
import disclosur found back report
believ codx under-valued support belief two valuat techniqu purpos
determin price target use discount futur earn model follow valuat techniqu
use
discount valu futur earn use price target see figur
valuat rel peer see figur
discount futur earn basi price
price target base discount earn model assumpt compani
reach break-even experi signific growth valuat model shown figur
model project price target round model sum earn per share
discount arriv per share valu near-term ep grow rapidli lower year
note model underst futur acquisit product market probabl underst tax benefit
offset earn never year
valuat rel peer
compar codx simpl averag peer figur share sell signific premium everi sale
metric howev two compani sell even higher multipl market clearli give compani scarciti
premium develop test arent lot tradabl option play
peopl expect soon grow valuat detail peer found figur near back
report compani use figur similar line busi although none perfect
import disclosur found back report
figur co-diagnost inc summari discount peer
premium
litchfield hill research llc refinitiv eikon
guidanc forecast
compani provid guidanc forecast assum break-out year reach break-even
difficult predict exactli break-even occur note million revenu
would repres market share billion billion test market detail figur
sinc compani last report result rais approxim million three regist direct offer
klepp ohtsuka klepp et al studi polynucleotid xcvi repair replic short synthet dna
catalyz dna polymeras mol biol
panet khorana hg studi polynucleotid linkag deoxyribopolynucleotid templat cellulos use
replic biol chem
saiki rk scharf faloona et al enzymat amplif beta-globin genom sequenc restrict site analysi
diagnosi sickl cell anemia scienc
mulli kb faloona fa specif synthesi dna vitro via polymerase-catalyz chain reaction method enzymol
import disclosur found back report
co-diagnost inc cdi molecular diagnost compani develop manufactur sell reagent
use diagnost test function via detect and/or analysi nucleic acid molecul dna rna use
proprietari test design system proprietari reagent codx design sell polymeras chain reaction pcr
diagnost test diseas pathogen start test tuberculosi drug resist tuberculosi
test hepat malaria dengu hiv zika viru test design verifi
compani laboratori tuberculosi test zika test triplex test zika dengu chikungunya receiv
ce mark qualifi test sold throughout european commun countri central
south america connect sale test may sell diagnost equip manufactur
self-contain lab system refer mdx devic
pcr polymeras chain reaction invalu tool molecular biolog research use laboratori around
world wide array applic clone gene express analysi genotyp sequenc
one well-known techniqu molecular biolog replic single-strand dna templat
use synthet primer dna polymeras first report earli nevertheless pcr
method know today amplifi target dna develop research tool kari mulli
sinc pcr becom integr part molecular biolog applic rang basic research
diseas diagnost agricultur test forens investig invent kari mulli award
nobel prize chemistri
pcr biochem process capabl amplifi singl dna molecul million copi short time
amplif achiev seri three step denatur double-strand dna templat
heat separ strand anneal short dna molecul call primer bind flank region
target dna extens dna polymeras extend end primer along templat
strand step repeat cycl time exponenti produc exact copi target dna
year fundament principl pcr remain method evolv vast
perform improv dna polymeras reagent well innov instrument plastic
vessel hold reaction
figur co-diagnost inc three step pcr
cdi develop pcr test sensit specif develop rapidli identifi new
pathogen genet diseas
cdi scientist first understand complex mathemat dna test design engin dna test
autom algorithm rapidli screen million possibl option pinpoint optimum design dr satterfield
chief technolog offic develop compani intellectu properti consist predict mathemat
algorithm proprietari reagent use test process togeth repres major advanc pcr
test system compani diagnost system enabl rapid low-cost molecular test organ
genet diseas autom histor complex procedur develop administr test
newest technic advanc involv novel approach pcr test design co-prim elimin one
key vex issu pcr amplif exponenti growth primer-dim pair produc fals posit
fals neg advers interfer identif target dna
codx design test identifi optim locat target gene amplif pair locat
optim primer probe structur achiev output meet design input requir identifi
market research done follow plan document process procedur test
word data result test verifi succeed design intend outset verif
import disclosur found back report
seri test conclud product readi proceed valid clinic evalu set
use initi product test confirm product design meet user need
technolog protect five grant one pend us patent well certain trade secret
copyright ownership proprietari platform give advantag avoid payment patent royalti
requir pcr test system also allow opportun sell diagnost test lower price
competitor still gener profit also sell leas portabl case laboratori equip
made other exist diagnost center sell reagent compris proprietari test
laboratori test facil
compani plan manufactur molecular diagnost test follow diseas follow region
sold along mdx devic
seek clearanc
 emerg use basi
caribbean central south
zika tuberculosi hepat
 dengu
tuberculosi hepat
papillomaviru hiv
version
tuberculosi hepat
compani file press releas
caribbean central south america market
initi sale entiti within caribbean public agenc member state anguilla antigua
dominica grenada haiti guyana jamaica montserrat saint kitt nevi saint lucia st maarten saint vincent
grenadin surinam trinidad tobago turk caico island
countri regulatori hurdl food drug administr fda grant
permiss cdi export mani product fda permiss export grant section
feder food drug cosmet act amend fdc act section fda act cover
certain medic devic yet receiv approv pre-market approv unit state fda
compani commenc pre-market approv step fda section appli medic
devic accept import countri manufactur fda manufactur
first offer zika test region demand test follow quickli test tuberculosi
hepat dengu full rang test product manufactur sale upon receipt purchas
order lab hospit
import disclosur found back report
compani enter jv agreement manufactur diagnost test seven infecti diseas
pharmaceut manufactur compani india cosara diagnost pvt ltd agreement provid
manufactur test name plant ranoli india joint sale market test
india also jv manufactur agreement synbiot
sinc test conduct india indian citizen fda approv inspect requir certain
indian regulatori approv central drug standard control organ cdsco must acquir
approv grant decemb
india countri highest burden tuberculosi world organ tuberculosi statist
india give estim incid figur million case tuberculosi india global
incid million
molecular diagnost govern europ framework vitro diagnost ivd encompass
diagnost product reagent instrument system intend use diagnosi diseas regulatori
system ivd built larg self-certif procedur place heavi respons manufactur non
self-certifi product subject standard self-certifi product subject audit review
notifi bodi prior receiv approv ce-mark ce-mark manufactur declar
product meet requir applic european commiss direct exampl current oblig
includ place qualit manufactur process user instruct clear fit purpos ensur
physic featur devic diagnost pose danger product fulfil relat
control requir may ce-mark indic product compliant eu legisl sold
european union receiv ce mark tuberculosi zika zika dengu chikungunya triplex test
receiv ce mark test feb
receiv iso iso certif relat design manufactur medic devic
product iso certif indic meet standard requir self-certifi certain product
affix ce-mark sale product countri accept ce mark includ unit state
minim government approv countri
believ compani receiv emerg approv fda coronaviru test immin
compani isnt plan offer test howev test may abl qualifi
laboratori develop test ldt diagnost test develop manufactur clia certifi
laboratori test develop lab use laboratori clia laboratori develop
perform characterist perform analyt valid ldt obtain licens offer
molecular diagnost market fast-grow portion vitro test tube base control environ
diagnost market use estim incid diseas center diseas control world
organ intern health agenc sourc includ estim believ market
could rang billion billion see figur lower rang billion exclud revenu test
relat higher estim assum billion test price per test vari number
factor purpos exampl assum averag cost would
import disclosur found back report
unit million
total
compani file litchfield hill research llc
believ sever advantag molecular test form diagnost test includ
higher sensit abil perform multiplex test fewer fals read abil test drug
resist individu gene
competit advantag co-diagnost
believ follow competit advantag
afford lower-cost test kit low-cost mdx-devic speed develop own
ip
flexibl cdi test design run mani vendor dna diagnost test machin
test particularli well suit new gener lab-on-a-chip point-of-car loc poc
highli portabl analysi machineri field clinic offic applic
abil develop new test new pathogen quickli believ rapid assay design system softwar
provid shorter time product releas
believ test accur competitor detect strain virus
exclus cdi own patent intellectu properti use prepar test
low-cost provid addit low overhead manufactur system lower cost countri platform
technolog obviat need pay patent royalti typic requir competitor use patent
test platform design test
import disclosur found back report
world-wide footprint dynam technolog encompass market world-wide compani
anticip identifi best target market high burden develop countri hbdc
also develop nation
combin product offer cdi ultra-sensit test well-design match new gener
handheld small point-of-car devic enter market use togeth afford
test devic may revolution molecular diagnost industri cost speed test result
multiplex initi develop effort demonstr co-prim design test abl
test multipl target sampl without distort caus fals neg fals posit
gener occur multiplex test
liquid biopsi cancer screen
develop practic liquid biopsi test like spur low cost test mani develop countri
believ compani liquid biopsi cancer screen readi test suffici develop
resourc dedic project medic applic single-nucleotid polymorph snp detect
technolog determin presenc cancer cell cell-fre genet materi liquid tissu biopsi
determin distinct type cancer involv real-lif exampl includ abl identifi specif
mutat gene link breast cancer order determin patient prognosi initi effect
afford treatment determin whether chemotherapi necessari
cdi technolog practic purpos essenti elimin primer-dim open uniqu
applic liquid biopsi cancer detect abil multiplex reaction test sever dna target
allow technician detect multipl cancer free-circul dna fragment whole cell blood sampl
time
snp detect also use agricultur industri identifi variat crop genom achiev improv seed
viabil desir characterist includ drought resist diseas resist pest resist higher
compani first approach larg agribusi evalu abil multiplex certain target
genom result develop project success demonstr abil multiplex
target genom target well project undertaken conjunct manufactur
coprim test result project encourag parent coprim manufactur seek world-wid
licens arrang coprim agricultur industri complet octob pursuant
exclus licens agrigenom industri license pay royalti coprim sold
license custom januari license formal introduc product larg agricultur confer
brand product sell bhqplex coprim
addit licens assay develop
addit uniqu properti coprim technolog make ideal suit varieti applic
sensit key optim result includ multiplex sever target enhanc snp detect enrich
next gen sequenc uniqu characterist coprim research compani institut
request compani design diagnost locat identifi uncommon gene sequenc
creat test target sequenc multiplex reaction applic technolog begin
stage believ result initi research indic signific step forward defin
capabl technolog believ translat revenu produc licens arrang
import disclosur found back report
molecular diagnost industri extrem competit mani firm provid
product cdi provid provid mani diagnost test yet develop mani competitor
larger cdi significantli greater financi resourc diagnost test industri compet
compani biomerieux siemen pharmaceut compani abbott
laboratori becton dickinson johnson johnson mani competitor includ figur
mr offic director sinc april mr engag privat invest busi
februari present senior execut data broadcast corpor lead provid
wireless real-tim financi market data news sophist fixed- incom portfolio analyt individu
profession investor co-found serv ceo chairman board
broadcast intern inc data broadcast corpor acquir broadcast intern
creat cb marketwatch lead financi news site particip initi public offer mr egan
prior experi direct public compani work capit market give valuabl experi
advis board matter financ oper
dr satterfield chief scienc offic director sinc april dr satterfield employ
compani januari present prior sole sharehold owner dna logix
inc januari januari dna logix develop patent technolog own
compani found co-diagnost april first field use engin mathemat
design new dna test technolog employ arcxi biotechnolog
develop new diagnost platform group depart homeland secur nation biodefens
analysi countermeasur center unit state armi medic research institut infecti diseas
sandia nation laboratori california depart public health numer other fellowship
depart homeland secur receiv ph bioengin emphasi
entrepreneurship intellectu properti law arizona state univers dual-enrol program uc
berkeley dr satterfield experi scienc underli compani product technolog give
valuabl experi advis board statu product posit diagnost test
mr benson chief offic secretari novemb present serv
cfo secretari gener counsel member board director broadcast intern inc publicli
trade commun servic compani secretari gener counsel data broadcast corpor
publicli trade provid market inform individu investor mr benson receiv degre
univers utah school law bachelor scienc degre account univers utah
mr benson becam certifi public account mr benson experi financ account
busi consult togeth role cfo prior public compani experi provid mr benson
expertis enabl critic input compani
import disclosur found back report
mayuranki almaula phd sr vice-president oversea oper strateg allianc
dr almaula respons establish clinic verif valid strategi support cdi diagnost
portfolio involv support india-bas clinic manufactur oper joint ventur cosara
diagnost pvt ltd dr almaula provid support establish relationship across multipl contin
compani includ insilico scienc busi develop director probe support
senior execut vice-president busi develop defin execut india strategi symbiosi
biowar intern busi develop strategi mayuranki complet master microbiolog
maharaja sayajirao univers baroda doctor microbiolog stanford univers
import disclosur found back report
litchfield hill research llc refinitiv eikon formerli thomson reuter eikon
import disclosur found back report
